163 related articles for article (PubMed ID: 23873303)
1. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours.
Rainczuk A; Rao JR; Gathercole JL; Fairweather NJ; Chu S; Masadah R; Jobling TW; Deb-Choudhury S; Dyer J; Stephens AN
Int J Cancer; 2014 Feb; 134(3):530-41. PubMed ID: 23873303
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
3. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
[TBL] [Abstract][Full Text] [Related]
5. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.
Martins FC; Santiago Id; Trinh A; Xian J; Guo A; Sayal K; Jimenez-Linan M; Deen S; Driver K; Mack M; Aslop J; Pharoah PD; Markowetz F; Brenton JD
Genome Biol; 2014 Dec; 15(12):526. PubMed ID: 25608477
[TBL] [Abstract][Full Text] [Related]
6. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
Bronger H; Singer J; Windmüller C; Reuning U; Zech D; Delbridge C; Dorn J; Kiechle M; Schmalfeldt B; Schmitt M; Avril S
Br J Cancer; 2016 Aug; 115(5):553-63. PubMed ID: 27490802
[TBL] [Abstract][Full Text] [Related]
7. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.
Delgado E; Boisen MM; Laskey R; Chen R; Song C; Sallit J; Yochum ZA; Andersen CL; Sikora MJ; Wagner J; Safe S; Elishaev E; Lee A; Edwards RP; Haluska P; Tseng G; Schurdak M; Oesterreich S
Gynecol Oncol; 2016 May; 141(2):348-356. PubMed ID: 26946093
[TBL] [Abstract][Full Text] [Related]
8. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
12. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
Bjersand K; Seidal T; Sundström-Poromaa I; Åkerud H; Skirnisdottir I
PLoS One; 2017; 12(6):e0179363. PubMed ID: 28609484
[TBL] [Abstract][Full Text] [Related]
13. [Expression of Notch1, Jagged1 and NICD in epithelial ovarian carcinomas and a preliminary study on the activity of gamma-secretase in epithelial ovarian carcinoma cell lines].
Feng Z; Wen H; Liao Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):780-6. PubMed ID: 25537253
[TBL] [Abstract][Full Text] [Related]
14. VAV1 represses E-cadherin expression through the transactivation of Snail and Slug: a potential mechanism for aberrant epithelial to mesenchymal transition in human epithelial ovarian cancer.
Wakahashi S; Sudo T; Oka N; Ueno S; Yamaguchi S; Fujiwara K; Ohbayashi C; Nishimura R
Transl Res; 2013 Sep; 162(3):181-90. PubMed ID: 23856093
[TBL] [Abstract][Full Text] [Related]
15. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
Köbel M; Madore J; Ramus SJ; Clarke BA; Pharoah PD; Deen S; Bowtell DD; Odunsi K; Menon U; Morrison C; Lele S; Bshara W; Sucheston L; Beckmann MW; Hein A; Thiel FC; Hartmann A; Wachter DL; Anglesio MS; Høgdall E; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Fogarty ZC; Vierkant RA; Liu S; Cho S; Nelson G; Ghatage P; Gentry-Maharaj A; Gayther SA; Benjamin E; Widschwendter M; Intermaggio MP; Rosen B; Bernardini MQ; Mackay H; Oza A; Shaw P; Jimenez-Linan M; Driver KE; Alsop J; Mack M; Koziak JM; Steed H; Ewanowich C; DeFazio A; Chenevix-Trench G; Fereday S; Gao B; Johnatty SE; George J; Galletta L; ; Goode EL; Kjær SK; Huntsman DG; Fasching PA; Moysich KB; Brenton JD; Kelemen LE
Br J Cancer; 2014 Dec; 111(12):2297-307. PubMed ID: 25349970
[TBL] [Abstract][Full Text] [Related]
17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
18. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Ardighieri L; Missale F; Bugatti M; Gatta LB; Pezzali I; Monti M; Gottardi S; Zanotti L; Bignotti E; Ravaggi A; Tognon G; Odicino F; Calza S; Missolo-Koussou Y; Ries CH; Helft J; Vermi W
Front Immunol; 2021; 12():690201. PubMed ID: 34220848
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.
Lundgren S; Berntsson J; Nodin B; Micke P; Jirström K
J Ovarian Res; 2016 Apr; 9():21. PubMed ID: 27048364
[TBL] [Abstract][Full Text] [Related]
20. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]